CANCAP02: A study into the pharmacodynamic biomarker effects of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (RP).

被引：0
|
作者：
Pacey, Simon
Corbacho, Javier Garcia
Shah, Nimish
Brat, Ola
Warren, Anne
Baird, Richard D.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.97
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
97
引用
收藏
页数：2
相关论文
共 31 条
  • [21] Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth
    Pi, Ruyu
    Yang, Yang
    Hu, Xiaoyi
    Li, Hongyi
    Shi, Houhui
    Liu, Yu
    Wang, Xi
    Tong, An
    Lu, Tianqi
    Wei, Yuquan
    Zhao, Xia
    Wei, Xiawei
    CANCER LETTERS, 2021, 523 : 72 - 81
  • [22] First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSe-ESMART trial
    Morscher, Raphael J.
    Brard, Caroline
    Berlanga, Pablo
    Marshall, Lynley, V
    Andre, Nicolas
    Rubino, Jonathan
    Aerts, Isabelle
    De Carli, Emilie
    Corradini, Nadege
    Nebchi, Souad
    Paoletti, Xavier
    Mortimer, Peter
    Lacroix, Ludovic
    Pierron, Gaelle
    Schleiermacher, Gudrun
    Vassal, Gilles
    Geoerger, Birgit
    EUROPEAN JOURNAL OF CANCER, 2021, 157 : 268 - 277
  • [23] Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells
    Li, Senmao
    Sheng, Jindong
    Liu, Zhenhua
    Fan, Yu
    Zhang, Cuijian
    Lv, Tianjing
    Hu, Shuai
    Jin, Jie
    Yu, Wei
    Song, Yi
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (05) : 2436 - 2449
  • [24] An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells
    Yu Mizutani
    Aki Inase
    Yimamu Maimaitili
    Yoshiharu Miyata
    Akihito Kitao
    Hisayuki Matsumoto
    Koji Kawaguchi
    Ako Higashime
    Hideaki Goto
    Keiji Kurata
    Kimikazu Yakushijin
    Hironobu Minami
    Hiroshi Matsuoka
    International Journal of Hematology, 2019, 110 : 490 - 499
  • [25] An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells
    Mizutani, Yu
    Inase, Aki
    Maimaitili, Yimamu
    Miyata, Yoshiharu
    Kitao, Akihito
    Matsumoto, Hisayuki
    Kawaguchi, Koji
    Higashime, Ako
    Goto, Hideaki
    Kurata, Keiji
    Yakushiji, Kimikazu
    Minami, Hironobu
    Matsuoka, Hiroshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (04) : 490 - 499
  • [26] Comprehensive PI3K pathway inhibition through combination of the PI3Kβ/δ inhibitor AZD8186 and the mTORC1/2 inhibitor AZD2014 drives tumor regression in vivo
    Hancox, Urs
    Polanska, Urszula
    Hanson, Lyndsay
    Ellston, Rebecca
    Maynard, Julia
    Kraus, Manfred
    Curwen, Jon
    Klinowska, Teresa
    Ward, Lara
    Cruzalegui, Francisco
    Green, Stephen
    Symeonides, Stefan
    Cronin, Kathryn
    Barry, Simon
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [27] Longitudinal patient-reported outcomes (PROs) and qualitative assessment of symptom burden within a phase 1b trial of a PARP inhibitor olaparib combined with an oral mTORC1/2 inhibitor (AZD2014) or an AKT inhibitor (AZD5363)
    Meyer, Larissa A.
    Sun, Charlotte
    Shi, Qiuling
    Westin, Shannon
    Haq, Shireen
    Savelieva, Katerina
    Coleman, Robert
    Mills, Gordon
    Williams, Loretta
    QUALITY OF LIFE RESEARCH, 2018, 27 : S77 - S77
  • [28] TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer
    Banerji, U.
    Basu, B.
    Spicer, J. F.
    Wilson, R.
    Hall, E.
    Sundar, R.
    Kumar, S.
    Wu, Y.
    Coyle, V.
    Carreira, S.
    Parmar, M.
    Dawes, J. C.
    Banerjee, S.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] The PI3Kbeta/delta inhibitor AZD8186 combines with the dual mTORC1/2 inhibitor AZD2014 to give comprehensive PI3K pathway inhibition and drive tumour regression in vivo
    Simon, B.
    Hancox, U.
    Polanska, U.
    Hanson, L.
    Dudley, P.
    Ellston, R.
    Maynard, J.
    Kraus, M.
    Curwen, J.
    Klinowska, T.
    Ward, L.
    Cruzalegui, F.
    Symeonides, S.
    Cronin, K.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 177 - 177
  • [30] Phase I study of orally administered 14Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies
    MacDonald, Alexander
    Scarfe, Graeme
    Magirr, Dominic
    Sarvotham, Tinnu
    Charlton, Julie
    Brugger, Wolfram
    Dean, Emma
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (04) : 787 - 795
1234